多黏菌素B在脓毒血症患者中的群体药动学研究

张俊, 张素枝, 孙志, 韩冰, 孔羽, 周霖, 朱振峰, 罗永刚, 张晓坚

中国药学杂志 ›› 2021, Vol. 56 ›› Issue (9) : 744-748.

PDF(1931 KB)
中国药学杂志
PDF(1931 KB)
中国药学杂志 ›› 2021, Vol. 56 ›› Issue (9) : 744-748. DOI: 10.11669/cpj.2021.09.009
论著

多黏菌素B在脓毒血症患者中的群体药动学研究

  • 张俊a, 张素枝a, 孙志a, 韩冰b, 孔羽b, 周霖a, 朱振峰a, 罗永刚b*, 张晓坚a*
作者信息 +

Population Pharmacokinetics of Polymyxin B in Patients with Sepsis

  • ZHANG Juna, ZHANG Su-zhia, SUN Zhia, HAN Bingb, KONG Yub, ZHOU Lina, ZHU Zhen-fenga, LUO Yong-gangb*, ZHANG Xiao-jiana*
Author information +
文章历史 +

摘要

目的 建立脓毒血症患者多黏菌素B(polymyxin B,PB)的群体药动学(population pharmacokinetic, PPK)模型。方法 收集16例多重耐药革兰阴性菌感染的患者第5剂静脉滴注PB前及滴注后12 h内的血药浓度,采用非线性混合效应程序建立PPK模型。结果 PB在脓毒血症患者中的药动学特性符合2-房室模型,未发现对PB药动学参数有影响的协变量,模型评价表明模型稳定,且有较好的预测效能,PB在脓毒血症患者中的剂量调整应参考药动学靶值和细菌的最低抑菌浓度(MIC)值。结论 本研究建立了脓毒血症患者PB的PPK模型,可为PB在中国成年脓毒血症患者中的个体化用药提供参考。

Abstract

OBJECTIVE To develop a population pharmacokinetics (PPK) model of polymyxin B (PB) in Chinese sepsis patients. METHODS A total of 16 ICU sepsis patients with multidrug-resistant Gram-negative bacterial infections were included. On the fifth dose, blood specimens were collected before PB administration and up to 12 h after PB dosing. The PPK model was developed by nonlinear mixed effects modeling. RESULTS The PPK character of PB was best described by a two-compartment model. No clinical tested data of patients was identified as a covariate affected the PK parameters of polymyxin B in the studied sepsis population. The individual PB dosage adjustment should based on the PK target and MIC of microorganism in sepsis patients. CONCLUSION The PPK model of PB in sepsis is established successfully and could provide basis for the individualized dosage regimen in adult sepsis patients.

关键词

多黏菌素B / 药动学 / 脓毒血症

Key words

polymyxin B / pharmacokinetics / sepsis

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
张俊, 张素枝, 孙志, 韩冰, 孔羽, 周霖, 朱振峰, 罗永刚, 张晓坚. 多黏菌素B在脓毒血症患者中的群体药动学研究[J]. 中国药学杂志, 2021, 56(9): 744-748 https://doi.org/10.11669/cpj.2021.09.009
ZHANG Jun, ZHANG Su-zhi, SUN Zhi, HAN Bing, KONG Yu, ZHOU Lin, ZHU Zhen-feng, LUO Yong-gang, ZHANG Xiao-jian. Population Pharmacokinetics of Polymyxin B in Patients with Sepsis[J]. Chinese Pharmaceutical Journal, 2021, 56(9): 744-748 https://doi.org/10.11669/cpj.2021.09.009
中图分类号： R969.1   

参考文献

[1] WANG M, WEI H, ZHAO Y, et al. Analysis of multidrug-resistant bacteria in 3 223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in China[J]. Bosn J Basic Med Sci, 2019, 19(1):86-93.
[2] MAO T, ZHAI H, DUAN G, et al. Patterns of drug-resistant bacteria in a general hospital, China, 2011-2016[J]. Pol J Microbiol, 2019, 68(2):225-232.
[3] CUNHA B A. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited[J]. Med Clin North Am, 2006, 90(6):1089-1107.
[4] ZAVASCKI A P, GOLDANI L Z, LI J, et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review[J]. J Antimicrob Chemother, 2007, 60(6):1206-1215.
[5] STORM D R, ROSENTHAL K S, SWANSON P E. Polymyxin and related peptide antibiotics[J]. Annu Rev Biochem, 1977, 46(1):723-763.
[6] ROBERTS J A, JOYNT G M, CHOI G Y, et al. How to optimise antimicrobial prescriptions in the intensive care unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics[J]. Int J Antimicrob Agents, 2012, 39(3):187-192.
[7] TSUJI B T, POGUE J M, ZAVASCKI A P, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)[J]. Pharmacotherapy, 2019, 39(1):10-39.
[8] MANCHANDANI P, THAMLIKITKUL V, DUBROVSKAYA Y, et al. Population pharmacokinetics of polymyxin B[J]. Clin Pharmacol Ther, 2018, 104(3):534-538.
[9] NICOLAU D P, QUINTILIANI R, NIGHTINGALE C H. Antibiotic kinetics and dynamics for the clinician[J]. Med Clin North Am, 1995, 79(3):477-495.
[10] SANDRI A M, LANDERSDORFER C B, JACOB J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens[J]. Clin Infect Dis, 2013, 57(4):524-531.
[11] COCKCROFT D W, GAULT M H. Prediction of creatinine clearance from serum creatinine[J]. Nephron, 1976, 16(1):31-41.
[12] YU X B, JIAO Z, ZHANG C H, et al. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions[J]. Br J Clin Pharmacol, 2020, 87(11):14576.
[13] KUBIN C J, NELSON B C, MIGLIS C, et al. Population pharmacokinetics of intravenous polymyxin B from clinical samples[J]. Antimicrob Agents Chemother, 2018, 62(3):e01493-17.
[14] WANG P, ZHANG Q, ZHU Z, et al. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections[J]. Front Pharmacol, 2020, 11:829.
[15] AVEDISSIAN S N, MIGLIS C, KUBIN C J, et al. Polymyxin B pharmacokinetics in adult cystic fibrosis patients[J]. Pharmacotherapy, 2018, 38(7):730-738.
[16] MIGLIS C, RHODES N J, AVEDISSIAN S N, et al. Population pharmacokinetics of polymyxin B in acutely Ⅲ adult patients[J]. Antimicrob Agents Chemother, 2018, 62(3):e01475-17.
[17] THAMLIKITKUL V, DUBROVSKAYA Y, MANCHANDANI P, et al. Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency[J]. Antimicrob Agents Chemother, 2017, 61(1):e01337-16.
[18] KUBIN C J, NELSON B C, MIGLIS C, et al. Population pharmacokinetics of intravenous polymyxin B from clinical samples[J]. Antimicrob Agents Chemother, 2018, 62(3):e01493-17.
[19] ZAVASCKI A P, GOLDANI L Z, CAO G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients[J]. Clin Infect Dis, 2008, 47(10):1298-1304.
[20] ELIAS L S, KONZEN D, KREBS J M, et al. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic[J]. J Antimicrob Chemother, 2010, 65(10):2231-2237.
[21] DUDHANI R V, TURNIDGE J D, NATION R L, et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models[J]. J Antimicrob Chemother, 2010, 65(9):1984-1990.

基金

河南省科技攻关项目资助(22170136,212102310321)
PDF(1931 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉